Log in

NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

$14.85
-0.56 (-3.63 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$14.75
Now: $14.85
$16.06
50-Day Range
$10.26
MA: $12.38
$15.43
52-Week Range
$5.75
Now: $14.85
$16.10
Volume1.86 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CYTK
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees130
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to the consensus estimate of $7.80 million. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

6 analysts have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

News stories about CYTK stock have been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytokinetics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a decline of 9.9% from the January 15th total of 9,400,000 shares. Based on an average trading volume of 913,000 shares, the short-interest ratio is currently 9.3 days. Approximately 15.7% of the company's stock are short sold. View Cytokinetics' Current Options Chain.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Bank of New York Mellon Corp (1.08%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, Credit Suisse AG and Barclays PLC. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $14.85.


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  647 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel